I-Mab Accelerates Givastomig Development With Global Phase 2 Trial In Metastatic Gastric Cancer; Expands Pipeline, And Appoints Wei Fu As Executive Chairman

Author: Benzinga Newsdesk | September 08, 2025 08:39am

• Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in combination with immunochemotherapy, in Q1 2026, with additional Phase 1b cohorts to follow
• Reiterates expectations to report topline givastomig Phase 1b dose expansion data in Q1 2026
• Plans to broaden the 1L development strategy into locally advanced gastric cancer as well as other Claudin 18.2-positive tumor types, including biliary tract cancer (BTC) and pancreatic ductal adenocarcinoma (PDAC)
• Mr. Wei Fu, I-Mab's Chairman of the Board of Directors, appointed as Executive Chairman, supported by further executive additions

ROCKVILLE, Md., Sept. 08, 2025 (GLOBE NEWSWIRE) --  I-Mab (NASDAQ:IMAB) (I-Mab or the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced accelerated investment in its lead program, givastomig, an investigational Claudin 18.2 (CLDN18.2)-directed bispecific antibody (CLDN18.2 x 4-1BB), including plans to initiate a global randomized Phase 2 study and additional Phase 1b cohorts. The Company also reiterated its expectations to report Phase 1b dose expansion data in Q1 2026. In addition, I-Mab announced leadership additions, including the appointment of Mr. Wei Fu as Executive Chairman, and the appointment of Dr. Sean Cao as Chief Business Development Officer (CBO).

Posted In: IMAB